FDA Drama & Psychedelic Setback — This Week in Biotech #58

Biotech Blueprint
27/06/2025 8 min

Listen "FDA Drama & Psychedelic Setback — This Week in Biotech #58"

Descargar episodio Ver en sitio original

Episode Synopsis

Subscribe for FREE HERE.FDA turmoil impacts key drug decisions, Compass’s phase 3 psilocybin data spooks investors, and Exelixis soars on cancer results (June 20–26, 2025).

More episodes of the podcast Biotech Blueprint

CDC’s Autism Reversal Shocks Experts, mRNA Flu Shot Advances, Big Oncology Wins - This Week in Biotech #79 24/11/2025
FDA Opens New Pathway, Pfizer’s $10B GLP-1 Win, and Biotech’s Return to Offense — This Week in Biotech #78 14/11/2025
Inside Sensible Biotechnologies: Reinventing mRNA Manufacturing 13/11/2025
Trump Reshapes Obesity Drug Prices, Novo Tops Pfizer Again — This Week in Biotech #77 08/11/2025
Novo tops Pfizer’s obesity bid; FDA moves to speed biosimilar approvals; Moderna–Merck rumors build — This Week in Biotech #76 31/10/2025
Drug launch prices soar; mRNA shots linked to longer cancer survival — This Week in Biotech #75 26/10/2025
How mRNA Could Defeat Latent Viruses and Train Immunity Against Cancer 21/10/2025
Trump cuts IVF & Medicaid drug prices; Novo buys Omeros; Lilly's GLP-1 orforglipron shines — This Week in Biotech #74 19/10/2025
Pharma Tariffs on Ice, FDA Limits Filings, Amgen’s PCSK9 Win — This Week in Biotech #72 Pharma Tariffs on Ice, FDA Limits Filings, Amgen’s PCSK9 Win — This Week in Biotech #72 03/10/2025
ACIP votes, Roche-89bio deal, Regeneron’s FOP win — This Week in Biotech #70 19/09/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA